{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:11:28Z","timestamp":1793293888116,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s11926-022-01060-y","type":"journal-article","created":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T09:06:56Z","timestamp":1646989616000},"page":"47-53","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Glucocorticoids in Myositis: Initiation, Tapering, and Discontinuation"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1675-597X","authenticated-orcid":false,"given":"Didem","family":"Saygin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chester V.","family":"Oddis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,11]]},"reference":[{"issue":"1","key":"1060_CR1","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12969-019-0326-5","volume":"17","author":"G Giancane","year":"2019","unstructured":"Giancane G, Lavarello C, Pistorio A, Oliveira SK, Zulian F, Cuttica R, et al. The PRINTO evidence-based proposal for glucocorticoids tapering\/discontinuation in new onset juvenile dermatomyositis patients. Pediatr Rheumatol Online J. 2019;17(1):24. https:\/\/doi.org\/10.1186\/s12969-019-0326-5.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"2 Suppl 1","key":"1060_CR2","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1212\/01.wnl.0000192262.29924.9e","volume":"66","author":"RC Griggs","year":"2006","unstructured":"Griggs RC. The current status of treatment for inclusion-body myositis. Neurology. 2006;66(2 Suppl 1):S30\u20132. https:\/\/doi.org\/10.1212\/01.wnl.0000192262.29924.9e.","journal-title":"Neurology"},{"issue":"6","key":"1060_CR3","first-page":"405","volume":"72","author":"EW Boland","year":"1950","unstructured":"Boland EW. The effects of cortisone and adrenocorticotropic hormone (ACTH) on certain rheumatic diseases. Calif Med. 1950;72(6):405\u201314.","journal-title":"Calif Med"},{"issue":"6","key":"1060_CR4","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1001\/archderm.1956.01550120001001","volume":"74","author":"LA Brunsting","year":"1956","unstructured":"Brunsting LA, Christianson HB, Perry HO. Dermatomyositis; unusual features, complications, and treatment. AMA Arch Derm. 1956;74(6):581\u20139.","journal-title":"AMA Arch Derm"},{"key":"1060_CR5","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1001\/archinte.1964.03860080113012","volume":"114","author":"PJ Vignos Jr","year":"1964","unstructured":"Vignos PJ Jr, Bowling GF, Watkins MP. Polymyositis; Effect of corticosteroids on final result. Arch Intern Med. 1964;114:263\u201377. https:\/\/doi.org\/10.1001\/archinte.1964.03860080113012.","journal-title":"Arch Intern Med"},{"issue":"8","key":"1060_CR6","first-page":"545","volume":"43","author":"RK Winkelmann","year":"1968","unstructured":"Winkelmann RK, Mulder DW, Lambert EH, Howard FM Jr, Diessner GR. Course of dermatomyositis-polymyositis: comparison of untreated and cortisone-treated patients. Mayo Clin Proc. 1968;43(8):545\u201356.","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"1060_CR7","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1093\/brain\/89.4.747","volume":"89","author":"AL Rose","year":"1966","unstructured":"Rose AL, Walton JN. Polymyositis: a survey of 89 cases with particular reference to treatment and prognosis. Brain. 1966;89(4):747\u201368. https:\/\/doi.org\/10.1093\/brain\/89.4.747.","journal-title":"Brain"},{"issue":"5","key":"1060_CR8","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1001\/archinte.1951.03810110092009","volume":"88","author":"C Sheard Jr","year":"1951","unstructured":"Sheard C Jr. Dermatomyositis. AMA Arch Intern Med. 1951;88(5):640\u201358. https:\/\/doi.org\/10.1001\/archinte.1951.03810110092009.","journal-title":"AMA Arch Intern Med"},{"issue":"4","key":"1060_CR9","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1212\/wnl.4.4.245","volume":"4","author":"LM Eaton","year":"1954","unstructured":"Eaton LM. The perspective of neurology in regard to polymyositis; a study of 41 cases. Neurology. 1954;4(4):245\u201363. https:\/\/doi.org\/10.1212\/wnl.4.4.245.","journal-title":"Neurology"},{"issue":"1\u20132","key":"1060_CR10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/s0165-5728(97)00033-7","volume":"76","author":"S Matsubara","year":"1997","unstructured":"Matsubara S, Hirai S, Sawa Y. Pulsed intravenous methylprednisolone therapy for inflammatory myopathies: evaluation of the effect by comparing two consecutive biopsies from the same muscle. J Neuroimmunol. 1997;76(1\u20132):75\u201380. https:\/\/doi.org\/10.1016\/s0165-5728(97)00033-7.","journal-title":"J Neuroimmunol"},{"issue":"3","key":"1060_CR11","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41584-020-0371-y","volume":"16","author":"RS Hardy","year":"2020","unstructured":"Hardy RS, Raza K, Cooper MS. Therapeutic glucocorticoids: mechanisms of actions in rheumatic diseases. Nat Rev Rheumatol. 2020;16(3):133\u201344. https:\/\/doi.org\/10.1038\/s41584-020-0371-y.","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"1060_CR12","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1002\/1529-0131(199805)41:5<761::AID-ART2>3.0.CO;2-M","volume":"41","author":"F Buttgereit","year":"1998","unstructured":"Buttgereit F, Wehling M, Burmester GR. A new hypothesis of modular glucocorticoid actions: steroid treatment of rheumatic diseases revisited. Arthritis Rheum. 1998;41(5):761\u20137. https:\/\/doi.org\/10.1002\/1529-0131(199805)41:5%3c761::AID-ART2%3e3.0.CO;2-M.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"1060_CR13","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1136\/thorax.55.7.603","volume":"55","author":"R Newton","year":"2000","unstructured":"Newton R. Molecular mechanisms of glucocorticoid action: what is important? Thorax. 2000;55(7):603\u201313. https:\/\/doi.org\/10.1136\/thorax.55.7.603.","journal-title":"Thorax"},{"issue":"8","key":"1060_CR14","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1136\/ard.61.8.718","volume":"61","author":"F Buttgereit","year":"2002","unstructured":"Buttgereit F, da Silva JA, Boers M, Burmester GR, Cutolo M, Jacobs J, et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis. 2002;61(8):718\u201322. https:\/\/doi.org\/10.1136\/ard.61.8.718.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1060_CR15","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1136\/jnnp.68.4.472","volume":"68","author":"T Mozaffar","year":"2000","unstructured":"Mozaffar T, Pestronk A. Myopathy with anti-Jo-1 antibodies: pathology in perimysium and neighbouring muscle fibres. J Neurol Neurosurg Psychiatry. 2000;68(4):472\u20138. https:\/\/doi.org\/10.1136\/jnnp.68.4.472.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"16","key":"1060_CR16","doi-asserted-by":"publisher","first-page":"9209","DOI":"10.1073\/pnas.97.16.9209","volume":"97","author":"K Nagaraju","year":"2000","unstructured":"Nagaraju K, Raben N, Loeffler L, Parker T, Rochon PJ, Lee E, et al. Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. Proc Natl Acad Sci U S A. 2000;97(16):9209\u201314. https:\/\/doi.org\/10.1073\/pnas.97.16.9209.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"1060_CR17","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1002\/art.20220","volume":"50","author":"AK Ulfgren","year":"2004","unstructured":"Ulfgren AK, Grundtman C, Borg K, Alexanderson H, Andersson U, Harris HE, et al. Down-regulation of the aberrant expression of the inflammation mediator high mobility group box chromosomal protein 1 in muscle tissue of patients with polymyositis and dermatomyositis treated with corticosteroids. Arthritis Rheum. 2004;50(5):1586\u201394. https:\/\/doi.org\/10.1002\/art.20220.","journal-title":"Arthritis Rheum"},{"key":"1060_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab597","author":"LS Hoff","year":"2021","unstructured":"\u2022 Hoff LS, de Souza FHC, Miossi R, Shinjo SK. Long-term effects of early pulse methylprednisolone and intravenous immunoglobulin in patients with dermatomyositis and polymyositis. Rheumatology (Oxford). 2021. https:\/\/doi.org\/10.1093\/rheumatology\/keab597. (Recent retrospective study showing higher rates of complete clinical response in patients treated with pulse dose steroids.)","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"1060_CR19","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1136\/jnnp.57.8.1008","volume":"57","author":"S Matsubara","year":"1994","unstructured":"Matsubara S, Sawa Y, Takamori M, Yokoyama H, Kida H. Pulsed intravenous methylprednisolone combined with oral steroids as the initial treatment of inflammatory myopathies. J Neurol Neurosurg Psychiatry. 1994;57(8):1008. https:\/\/doi.org\/10.1136\/jnnp.57.8.1008.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"1060_CR20","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1159\/000249745","volume":"167","author":"T Yanagisawa","year":"1983","unstructured":"Yanagisawa T, Sueishi M, Nawata Y, Akimoto T, Nozaki T, Koike T, et al. Methylprednisolone pulse therapy in dermatomyositis. Dermatologica. 1983;167(1):47\u201351. https:\/\/doi.org\/10.1159\/000249745.","journal-title":"Dermatologica"},{"key":"1060_CR21","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/978-1-4615-4857-7_54","volume":"455","author":"HD Bolosiu","year":"1999","unstructured":"Bolosiu HD, Man L, Rednic S. The effect of methylprednisolone pulse therapy in polymyositis\/dermatomyositis. Adv Exp Med Biol. 1999;455:349\u201357. https:\/\/doi.org\/10.1007\/978-1-4615-4857-7_54.","journal-title":"Adv Exp Med Biol"},{"issue":"2","key":"1060_CR22","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/art.23341","volume":"59","author":"KA Rouster-Stevens","year":"2008","unstructured":"Rouster-Stevens KA, Gursahaney A, Ngai KL, Daru JA, Pachman LM. Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis. Arthritis Rheum. 2008;59(2):222\u20136. https:\/\/doi.org\/10.1002\/art.23341.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"1060_CR23","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/0301-0082(90)90026-d","volume":"35","author":"KG Henriksson","year":"1990","unstructured":"Henriksson KG, Lindvall B. Polymyositis and dermatomyositis 1990\u2013diagnosis, treatment and prognosis. Prog Neurobiol. 1990;35(3):181\u201393. https:\/\/doi.org\/10.1016\/0301-0082(90)90026-d.","journal-title":"Prog Neurobiol"},{"issue":"4","key":"1060_CR24","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/0002-9343(93)90148-i","volume":"94","author":"MM Joffe","year":"1993","unstructured":"Joffe MM, Love LA, Leff RL, Fraser DD, Targoff IN, Hicks JE, et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med. 1993;94(4):379\u201387. https:\/\/doi.org\/10.1016\/0002-9343(93)90148-i.","journal-title":"Am J Med"},{"key":"1060_CR25","doi-asserted-by":"publisher","unstructured":"Espinosa-Ortega F, Holmqvist M, Dastmalchi M, Lundberg IE, Alexanderson H. Factors associated with treatment response in patients with idiopathic inflammatory myopathies. A registry-based study. Arthritis Care Res (Hoboken). 2020. https:\/\/doi.org\/10.1002\/acr.24498.","DOI":"10.1002\/acr.24498"},{"issue":"4","key":"1060_CR26","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/j.1600-0404.1982.tb03087.x","volume":"65","author":"KG Henriksson","year":"1982","unstructured":"Henriksson KG, Sandstedt P. Polymyositis--treatment and prognosis A study of 107 patients. Acta Neurol Scand. 1982;65(4):280\u2013300. https:\/\/doi.org\/10.1111\/j.1600-0404.1982.tb03087.x.","journal-title":"Acta Neurol Scand"},{"issue":"4","key":"1060_CR27","first-page":"441","volume":"17","author":"A Nzeusseu","year":"1999","unstructured":"Nzeusseu A, Brion F, Lefebvre C, Knoops P, Devogelaer JP, Houssiau FA. Functional outcome of myositis patients: can a low-dose glucocorticoid regimen achieve good functional results? Clin Exp Rheumatol. 1999;17(4):441\u20136.","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"1060_CR28","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1136\/ard.30.2.149","volume":"30","author":"AB Myles","year":"1971","unstructured":"Myles AB, Bacon PA, Daly JR. Single daily dose corticosteroid treatment Effect on adrenal function and therapeutic efficacy in various diseases. Ann Rheum Dis. 1971;30(2):149\u201353.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1060_CR29","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/BF00313897","volume":"232","author":"M Uchino","year":"1985","unstructured":"Uchino M, Araki S, Yoshida O, Uekawa K, Nagata J. High single-dose alternate-day corticosteroid regimens in treatment of polymyositis. J Neurol. 1985;232(3):175\u20138. https:\/\/doi.org\/10.1007\/BF00313897.","journal-title":"J Neurol"},{"issue":"2","key":"1060_CR30","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1159\/000338474","volume":"68","author":"M Uchino","year":"2012","unstructured":"Uchino M, Yamashita S, Uchino K, Hara A, Koide T, Suga T, et al. Long-term outcome of polymyositis treated with high single-dose alternate-day prednisolone therapy. Eur Neurol. 2012;68(2):117\u201321. https:\/\/doi.org\/10.1159\/000338474.","journal-title":"Eur Neurol"},{"issue":"1","key":"1060_CR31","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/00005792-197601000-00003","volume":"55","author":"L Axelrod","year":"1976","unstructured":"Axelrod L. Glucocorticoid therapy. Medicine (Baltimore). 1976;55(1):39\u201365. https:\/\/doi.org\/10.1097\/00005792-197601000-00003.","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"1060_CR32","first-page":"807","volume":"15","author":"CV Oddis","year":"1988","unstructured":"Oddis CV, Medsger TA Jr. Relationship between serum creatine kinase level and corticosteroid therapy in polymyositis-dermatomyositis. J Rheumatol. 1988;15(5):807\u201311.","journal-title":"J Rheumatol"},{"issue":"6","key":"1060_CR33","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.nmd.2010.03.011","volume":"20","author":"J van de Vlekkert","year":"2010","unstructured":"\u2022 van de Vlekkert J, Hoogendijk JE, de Haan RJ, Algra A, van der Tweel I, van der Pol WL, et al. Oral dexamethasone pulse therapy versus daily prednisolone in sub-acute onset myositis, a randomised clinical trial. Neuromuscul Disord. 2010;20(6):382\u20139. https:\/\/doi.org\/10.1016\/j.nmd.2010.03.011. (One of the few randomized controlled trials conducted to assess different glucocorticoid regimens in myositis.)","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"1060_CR34","doi-asserted-by":"publisher","first-page":"182","DOI":"10.7326\/0003-4819-81-2-182","volume":"81","author":"AL Metzger","year":"1974","unstructured":"Metzger AL, Bohan A, Goldberg LS, Bluestone R, Pearson CM. Polymyositis and dermatomyositis: combined methotrexate and corticosteroid therapy. Ann Intern Med. 1974;81(2):182\u20139. https:\/\/doi.org\/10.7326\/0003-4819-81-2-182.","journal-title":"Ann Intern Med"},{"issue":"1","key":"1060_CR35","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/art.1780240107","volume":"24","author":"TW Bunch","year":"1981","unstructured":"Bunch TW. Prednisone and azathioprine for polymyositis: long-term followup. Arthritis Rheum. 1981;24(1):45\u20138. https:\/\/doi.org\/10.1002\/art.1780240107.","journal-title":"Arthritis Rheum"},{"issue":"7688","key":"1060_CR36","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/s0140-6736(71)80005-3","volume":"1","author":"MC Sokoloff","year":"1971","unstructured":"Sokoloff MC, Goldberg LS, Pearson CM. Treatment of corticosteroid-resistant polymyositis with methotrexate. Lancet. 1971;1(7688):14\u20136. https:\/\/doi.org\/10.1016\/s0140-6736(71)80005-3.","journal-title":"Lancet"},{"key":"1060_CR37","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-021-05767-8","author":"J Loarce-Martos","year":"2021","unstructured":"\u2022 Loarce-Martos J, Lilleker JB, Alder E, Goode J, Chinoy H. Perspectives on glucocorticoid usage in patients with adult inflammatory myopathy. Clin Rheumatol. 2021. https:\/\/doi.org\/10.1007\/s10067-021-05767-8. (Recent survey study reporting perspectives of the patients with myositis on glucocorticoid use.)","journal-title":"Clin Rheumatol"},{"issue":"4","key":"1060_CR38","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1136\/annrheumdis-2012-201849","volume":"72","author":"P Azali","year":"2013","unstructured":"Azali P, Barbasso Helmers S, Kockum I, Olsson T, Alfredsson L, Charles PJ, et al. Low serum levels of vitamin D in idiopathic inflammatory myopathies. Ann Rheum Dis. 2013;72(4):512\u20136. https:\/\/doi.org\/10.1136\/annrheumdis-2012-201849.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1060_CR39","doi-asserted-by":"publisher","first-page":"102782","DOI":"10.1016\/j.autrev.2021.102782","volume":"20","author":"M Cox","year":"2021","unstructured":"Cox M, Sandler RD, Matucci-Cerinic M, Hughes M. Bone health in idiopathic inflammatory myopathies. Autoimmun Rev. 2021;20(4):102782. https:\/\/doi.org\/10.1016\/j.autrev.2021.102782.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"1060_CR40","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1186\/s12891-020-03448-2","volume":"21","author":"A Vincze","year":"2020","unstructured":"Vincze A, Bodoki L, Szabo K, Nagy-Vincze M, Szalmas O, Varga J, et al. The risk of fracture and prevalence of osteoporosis is elevated in patients with idiopathic inflammatory myopathies: cross-sectional study from a single Hungarian center. BMC Musculoskelet Disord. 2020;21(1):426. https:\/\/doi.org\/10.1186\/s12891-020-03448-2.","journal-title":"BMC Musculoskelet Disord"},{"issue":"5","key":"1060_CR41","doi-asserted-by":"publisher","first-page":"913","DOI":"10.4103\/2230-8210.117215","volume":"17","author":"A Gupta","year":"2013","unstructured":"Gupta A, Gupta Y. Glucocorticoid-induced myopathy: pathophysiology, diagnosis, and treatment. Indian J Endocrinol Metab. 2013;17(5):913\u20136. https:\/\/doi.org\/10.4103\/2230-8210.117215.","journal-title":"Indian J Endocrinol Metab"},{"issue":"7","key":"1060_CR42","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1056\/NEJMc2004843","volume":"382","author":"M Walsh","year":"2020","unstructured":"Walsh M, Merkel PA, Peh CA, Szpirt WM, Puechal X, Fujimoto S, et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med. 2020;382(7):622\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1803537-42.","journal-title":"N Engl J Med"},{"issue":"4","key":"1060_CR43","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1613849","volume":"377","author":"JH Stone","year":"2017","unstructured":"Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377(4):317\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1613849.","journal-title":"N Engl J Med"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-022-01060-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11926-022-01060-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-022-01060-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T07:57:34Z","timestamp":1647935854000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11926-022-01060-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["1060"],"URL":"https:\/\/doi.org\/10.1007\/s11926-022-01060-y","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"4 January 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent."}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}